Chronic Lymphocytic LeukemiaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

2000 records returned

Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 20, 2009 Category: Cancer & Oncology Tags: Lymphoma / Leukemia / Myeloma Source Type: news

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Although activation of the B-cell receptor (BCR) signaling pathway is implicated in the pathogenesis of chronic lymphocytic leukemia (CLL), its clinical impact and the molecular correlates of such response are not clearly defined. T-cell leukemia 1 (TCL1), the AKT modulator and proto-oncogene, is differentially expressed in CLL and linked to its pathogenesis based on CD5+ B-cell expansions arising in TCL1-transgenic mice. We studied here the association of TCL1 levels and its intracellular dynamics with the in vitro responses to BCR stimulation in 70 CLL cases. The growth kinetics after BCR engagement correlated strongly w...
Source: Blood - November 19, 2009 Category: Hematology Authors: Herling, M., Patel, K. A., Weit, N., Lilienthal, N., Hallek, M., Keating, M. J., Jones, D. Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: journals

TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We examined whether TAPP can regulate cell adhesion, a known function of utrophin/syntrophin in other cell types. Expression of membrane-targeted TAPP2 enhanced B-cell adhesion to fibronectin and laminin, whereas PH domain–mutant TAPP2 inhibited adhesion. siRNA knockdown of TAPP2 or utrophin, or treatment with PI3K inhibitors, significantly inhibited adhesion. These findings identify TAPP2 as a novel link between PI3K signaling and the cytoskeleton with potential relevance for leukemia progression. (Source: Blood)
Source: Blood - November 19, 2009 Category: Hematology Authors: Costantini, J. L., Cheung, S. M. S., Hou, S., Li, H., Kung, S. K., Johnston, J. B., Wilkins, J. A., Gibson, S. B., Marshall, A. J. Tags: Lymphoid Neoplasia Source Type: journals

Asymptomatic diffuse "encephalitic" cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia: case report and review of the literature.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We describe a 70 year old male with stage IV chronic lymphocytic leukemia complicated by aplastic anemia. Neurological examination and imaging revealed no significant abnormalities. At autopsy, the brain revealed multifocal cysts and free tachyzoites of Toxoplasma gondii with diffuse microglial nodules and no necrosis. To the best of our knowledge, this case represents the first report of the "encephalitic" form of toxoplasmosis in a non-AIDS patient. PMID: 19918334 [PubMed - in process] (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - November 19, 2009 Category: Pathology Authors: Abedalthagafi M, Rushing EJ, Garvin D, Cheson B, Ozdemirli M Tags: Int J Clin Exp Pathol Source Type: journals

US FDA issues complete response letter for Rituxan/MabThera for chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the US Food and Drug Administration (FDA) issued a complete response to Genentech, a wholly-owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) on the companies’ applications for Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for the treatment of for the treatment of patients with previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - November 18, 2009 Category: Pharmaceuticals Source Type: organizations

New treatments are available for chronic lymphocytic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DEAR MAYO CLINIC: I was recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. My doctor's approach is to "watch and wait." I'm uncomfortable with watchful waiting. Is there more... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - November 18, 2009 Category: American Health Source Type: news

Abscopal effect in a patient with chronic lymphocytic leukemia during radiation therapy: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a documented observation of Abscopal effect in a patient of Chronic Lymphocytic Leukemia during radiation therapy. (Source: BioMed Central)
Source: BioMed Central - November 18, 2009 Category: Journals (General) Authors: Preethi Bangalore LakshmangowdaLokesh ViswanathNaveen ThimmaiahLokanath DasappaSanjay Sudakar SupePramod Kallur Source Type: journals

Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cancer precursor/progenitor cells may initiate and sustain the growth of tumors, but evidence for their existence in human disease is indirect, relying on their in vitro properties and animal models. More directly, specific elimination of these rare cells from cancer patients should produce a delayed but progressive disappearance of differentiated malignant progeny. Here, we describe selective eradication of a putative precursor population in a patient with B-cell chronic lymphocytic leukemia, followed 6 months later by a progressive loss of mature tumor cells without further treatment. This outcome supports the presence o...
Source: Molecular Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Aaron FosterFatma OkurEttore BiagiAn LuGianpietro DottiEric YvonBarbara SavoldoGeorge CarrumMichael AndreeffMargaret GoodellHelen HeslopMalcolm Brenner Source Type: journals

NF-kappaB as a Prognostic Marker and Therapeutic Target in Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article discusses the importance of constitutive and inducible DNA binding of the transcription factor NF-kappaB in chronic lymphocytic leukemia. Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 17, 2009 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Current and Emerging Treatments for Chronic Lymphocytic LeukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Drugs)
Source: Drugs - November 16, 2009 Category: Drugs & Pharmacology Authors: Robak, TadeuszJamroziak, KrzysztofRobak, Pawel Tags: Review Articles Source Type: journals

NICE Draft Backs Rituximab for Relapsed or Refractory Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rituximab would be authorized to treat relapsed or refractory chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide under a draft guideline published by the clinical effectiveness... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - November 13, 2009 Category: Cancer & Oncology Source Type: news

Sonic Hedgehog Signaling Proteins and ATP-Binding Cassette G2 Are Aberrantly Expressed in Diffuse Large B-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
How does the expression of sonic hedgehog signaling proteins compare among diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia? Modern Pathology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 13, 2009 Category: Cancer & Oncology Tags: Pathology & Lab Medicine Source Type: info

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Marrow stromal cells (MSCs) provide important survival and drug resistance signals to chronic lymphocytic leukemia (CLL) cells, but current models to analyze CLL–MSC interactions are heterogeneous. Therefore, we tested different human and murine MSC lines and primary human MSCs for their ability to protect CLL cells from spontaneous and drug-induced apoptosis. Our results show that both human and murine MSCs are equally effective in protecting CLL cells from fludarabine-induced apoptosis. This protective effect was sustained over a wide range of CLL–MSC ratios (5:1 to 100:1), and the levels of protection were r...
Source: Blood - November 12, 2009 Category: Hematology Authors: Kurtova, A. V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M. P., Sivina, M., Wierda, W. G., Estrov, Z., Keating, M. J., Shehata, M., Jager, U., Gandhi, V., Kay, N. E., Plunkett, W., Burger, J. A. Tags: Lymphoid Neoplasia Source Type: journals

Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Several studies indicate that the development of chronic lymphocytic leukemia (CLL) may be influenced by antigen recognition through the clonotypic B-cell receptors (BCRs). However, it is still unclear whether antigen involvement is restricted to the malignant transformation phase or whether the putative antigen(s) may continuously trigger the CLL clone and affect not only the progenitor cell but also the leukemic cells themselves. To address this issue, we conducted a large-scale subcloning study of rearranged immunoglobulin heavy variable (IGHV) genes of diverse mutational status from 71 CLL cases (total, 1496 subcloned ...
Source: Blood - November 12, 2009 Category: Hematology Authors: Sutton, L.-A., Kostareli, E., Hadzidimitriou, A., Darzentas, N., Tsaftaris, A., Anagnostopoulos, A., Rosenquist, R., Stamatopoulos, K. Tags: Lymphoid Neoplasia Source Type: journals

Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We examined leukemia cell turnover in Eµ-TCL1 transgenic (TCL1-Tg) mice, which develop a CLL-like disease at 8 to 12 months of age. We found that leukemia cells in these mice not only had higher proportions of proliferating cells but also apoptotic cells than did nonleukemic lymphocytes. We crossed TCL1-Tg with BAFF-Tg mice, which express high levels of CD257. TCL1xBAFF-Tg mice developed CLL-like disease at a significantly younger age and had more rapid disease progression and shorter survival than TCL1-Tg mice. Leukemia cells of TCL1xBAFF-Tg mice had similar proportions of proliferating cells, but fewer proportions ...
Source: Blood - November 12, 2009 Category: Hematology Authors: Enzler, T., Kater, A. P., Zhang, W., Widhopf, G. F., Chuang, H.-Y., Lee, J., Avery, E., Croce, C. M., Karin, M., Kipps, T. J. Tags: Lymphoid Neoplasia Source Type: journals

A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage displayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment available for patients with B-cell chronic lymphocytic leukemia (B-CLL). Here, we show that post-alloHSCT antibody repertoires can be mined for the discovery of fully human monoclonal antibodies to B-CLL cell-surface antigens. Sera collected from B-CLL patients at defined times after alloHSCT showed selective binding to primary B-CLL cells. Pre-alloHSCT sera, donor sera, and control sera were negative. To identify post-alloHSCT serum antibodies and subsequently B-CLL cell-surface antigens they recognize, we generated a ...
Source: Blood - November 12, 2009 Category: Hematology Authors: Baskar, S., Suschak, J. M., Samija, I., Srinivasan, R., Childs, R. W., Pavletic, S. Z., Bishop, M. R., Rader, C. Tags: Transplantation, Lymphoid Neoplasia Source Type: journals

Hunting for the Achilles' heel of CLLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Blood)
Source: Blood - November 12, 2009 Category: Hematology Authors: Byrd, J. C. Tags: INSIDE BLOOD Source Type: journals

Newer, More Effective Treatments Are Available for Those With Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DEAR MAYO CLINIC: I was recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. My doctor's approach is to "watch and wait." I'm uncomfortable with watchful waiting. Is there more... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - November 12, 2009 Category: American Health Source Type: news

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study the efficacy of a first-line in vivo therapy was compared with treatment by R-roscovitine (ROSC) alone or by purine analogues (cladribine and fludarabine) combined with maphosphamide for 14 CLL patients under ex vivo conditions. ROSC induced the highest reduction in numbers of living B-cells, coinciding with an increased rate of apoptosis. After 24 h the percentage of apoptotic cells in ROSC-treated cultures was markedly higher than in untreated controls. ROSC also induced strong activation of the apoptosome and effector caspases in CLL cells. During progression of apoptosis the plasma membrane became permeab...
Source: Journal of Cellular Biochemistry - November 12, 2009 Category: Biochemistry Authors: Ma[lstrok]gorzata Rogali[nacute]ska, Jerzy Z. B[lstrok]o[nacute]ski, Oxana Komina, Pawe[lstrok] Góralski, Jolanta D. [Zdot]o[lstrok]nierczyk, Henryk Piekarski, Tadeusz Robak, Zofia M. Kilia[nacute]ska, Józefa W[eogon]sierska-G[aogon]dek Source Type: journals

Ofatumumab Receives Approval for CLLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration approved ofatumumab (Arzerra) for patients with chronic lymphocytic leukemia (CLL) whose cancer is no longer being controlled by other forms of chemotherapy. The product was approved under the FDA’s accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

NICE issues ACD on rituximab for relapsed chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: News NICE has issued an Appraisal Consultation Document on rituximab for relapsed chronic lymphocytic leukaemia. The preliminary recommendations are as follows: . Rituximab in combination with fludarabine and cyclophosphamide is recommended as an option for the treatment of relapsed or refractory chronic lymphocytic leukaemia except when the condition is refractory to fludarabine (i.e. not responded to fludarabine or has relapsed within 6 months of treatment) or has previously been treated with rituximab. . Rituximab in combination with chemotherapy agents other than flud...
Source: NeLM - Oncology - November 10, 2009 Category: Cancer & Oncology Source Type: organizations

The utility of a prognostic index for predicting time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL): the GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto) experience.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The results of this study extend the utility of a new prognostic index for predicting TFT in a large sample series of community-based patients with early CLL stage at presentation. Finally, our effort to develop a revised scoring method meets the need to dissect Binet stage A patients into different prognostic groups suitable for devising individualized and tailored follow-up during the treatment-free period. PMID: 19903673 [PubMed - as supplied by publisher] (Source: Haematologica)
Source: Haematologica - November 10, 2009 Category: Hematology Authors: Molica S, Mauro FR, Callea V, Giannarelli D, Lauria F, Rotoli B, Cortelezzi A, Liso V, Foà R Tags: Haematologica Source Type: journals

A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Deletion 13q14 on fluorescence in situ hybridization (FISH) analysis is the most common cytogenetic abnormality in chronic lymphocytic leukaemia (CLL), and is a favourable prognostic biomarker when detected as a sole abnormality. We intensively interrogated clinical outcome in 323 consecutive, untreated CLL patients with isolated 13q- identified within 2 years of diagnosis. We also analyzed outcome in 217 additional patients with deletion 11q22.3 or 17p13.1, or trisomy 12, based on whether these occurred in isolation or in conjunction with 13q-. Patients with a heterozygous 13q- and those with a homozygous deletion had sim...
Source: British Journal of Haematology - November 8, 2009 Category: Hematology Authors: Daniel L. Van Dyke, Tait D. Shanafelt, Timothy G. Call, Clive S. Zent, Stephanie A. Smoley, Kari G. Rabe, Susan M. Schwager, Jessica C. Sonbert, Susan L. Slager, Neil E. Kay Source Type: journals

Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4+ perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotypeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We have previously shown an expansion of cytotoxic antigen-experienced CD4+T cells (CTLs) that express perforin (PF) in the peripheral blood of patients with B cell chronic lymphocytic leukaemia (B-CLL). Increased frequencies of CD4+CTLs have since been attributed to chronic viral infections, particularly, human cytomegalovirus (HCMV). The present study examined the involvement of CD4+CTLs in responses to HCMV in B-CLL, and characterized their differentiation. We studied 36 HCMV seropositive (SP) and seronegative B-CLL patients and 20 healthy age-matched individuals. The HCMV reactivity of CD4+PF+ and CD4+PF[minus] cells w...
Source: British Journal of Haematology - November 6, 2009 Category: Hematology Authors: James A. Walton, Peter M. Lydyard, Amit Nathwani, Vincent Emery, Arne Akbar, Martin J. Glennie, Nino Porakishvili Source Type: journals

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this report, blood and bone marrow (BM) cCD52 and cCD20 were measured at response assessment in previously treated (N = 235) patients with CLL who received fludarabine, cyclophosphamide, and rituximab (FCR). Univariate and multivariate statistical models evaluated correlations of pre- and response variables with progression-free (PFS) and overall survival (OS). Response variables included 1996 National Cancer Institute-Working Group (NCI-WG) response, polymerase chain reaction (PCR) for immunoglobulin heavy chain (IGHV) in BM, and cCD52 and cCD20 levels (blood and BM) at response assessment. Using multivariate analysis,...
Source: British Journal of Haematology - November 6, 2009 Category: Hematology Authors: Gheath Alatrash, Maher Albitar, Susan O'Brien, Xuemei Wang, Taghi Manshouri, Stefan Faderl, Alessandra Ferrajoli, Jan Burger, Guillermo Garcia-Manero, Hagop M. Kantarjian, Susan Lerner, Michael J. Keating, William G. Wierda Source Type: journals

Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pim kinases are involved in B-cell development and are overexpressed in B-cell chronic lymphocytic leukemia (CLL). We hypothesized that Pim kinase inhibition would affect B-cell survival. Identified from a screen of imidazo[1,2-b]pyridazine compounds, SGI-1776 inhibits Pim-1, Pim-2, and Pim-3. Treatment of CLL cells with SGI-1776 results in a concentration-dependent induction of apoptosis. To elucidate its mechanism of action, we evaluated the effect of SGI-1776 on Pim kinase function. Unlike in replicating cells, phosphorylation of traditional Pim-1 kinase targets, phospho-Bad (Ser112) and histone H3 (Ser10), and cell-cyc...
Source: Blood - November 5, 2009 Category: Hematology Authors: Chen, L. S., Redkar, S., Bearss, D., Wierda, W. G., Gandhi, V. Tags: Lymphoid Neoplasia Source Type: journals

Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Premature termination codon (PTC) mutations are due to insertion or deletion of nucleotides causing a frameshift and premature termination codon in RNA. These transcripts are degraded by the nonsense-mediated decay pathway and have a very short half-life. We used a microarray technique to screen for genes that up-regulate their RNA signal upon nonsense-mediated decay pathway blockade in chronic lymphocytic leukemia (CLL) specimens and identified an E-cadherin transcript with PTC. Sequencing revealed an aberrant E-cadherin transcript lacking exon 11, resulting in a frameshift and PTC. The aberrant E-cadherin transcript was ...
Source: Blood - November 5, 2009 Category: Hematology Authors: Sharma, S., Lichtenstein, A. Tags: Lymphoid Neoplasia Source Type: journals

Gammaplex (human normal immunoglobulin) - New ProductEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Gammplex 5% w/w immunoglobulin, indicated for replacement therapy in: Primary immunodeficiency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiency - Wiskott Aldrich syndrome Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. Children with congenital AIDS and recurrent infections. Refer to SPC for full details (Source: NeLM - Immunology and vaccination)
Source: NeLM - Immunology and vaccination - November 5, 2009 Category: Allergy & Immunology Source Type: organizations

Expression of the Brain Transcription Factor OTX1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive Non-Hodgkin Lymphoma.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study identifies OTX1 as a molecular marker for high-grade GC-derived NHL and suggests an involvement of this transcription factor in B-cell lymphomagenesis. Furthermore, OTX1 expression in a subset of normal GC B cells carrying plasma cell markers suggests its possible contribution to terminal B-cell differentiation. PMID: 19893048 [PubMed - as supplied by publisher] (Source: The American Journal of Pathology)
Source: The American Journal of Pathology - November 5, 2009 Category: Pathology Authors: Omodei D, Acampora D, Russo F, De Filippi R, Severino V, Di Francia R, Frigeri F, Mancuso P, De Chiara A, Pinto A, Casola S, Simeone A Tags: Am J Pathol Source Type: journals

[Autoimmune hemolytic anemia.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background. Knowledge of autoimmune hemolytic anemia is rapidly increasing, especially on pathogenesis, associated disorders and aspects of transfusion immunology. New treatment options have emerged. Material and method. This review is based on selected publications, a non-systematic search in PubMed and the authors' own research. Results. Autoimmune hemolytic anemia is a heterogeneous group of diseases. The warm-antibody type is frequently associated with chronic lymphocytic leukemia or autoimmune systemic disease. Corticosteroids are still the first-line therapy and splenectomy is second-line, while rituximab has bec...
Source: Tidsskrift for den Norske Laegeforening - November 5, 2009 Category: Journals (General) Authors: Berentsen S, Sundic T, Hervig T, Tjønnfjord GE Tags: Tidsskr Nor Laegeforen Source Type: journals

Leukaemia drug testedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Although the study shows that PBOX-15 can kill isolated human CLL cells in the laboratory, it cannot reliably predict what other effects it might have in a living body. There are many stages to developing and testing potential new drugs, which can take many years and are not guaranteed to be successful. The early development stages involve laboratory studies such as this one, which are used to identify the effects of the drug on affected cells and tissues. These early tests are important to establish whether future research is worthwhile. Following the results of this initial study, the drug seems to be a cand...
Source: NHS News Feed - November 3, 2009 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions In addition to mantle cell lymphoma, SOX11 is strongly expressed only in lymphoblastic malignancies and Burkitt's lymphomas. Its expression is independent of cyclin D1 (except for weak expression in hairy cell leukemias) and unlikely to be due to translocations in lymphoid neoplasia. PMID: 19880779 [PubMed - in process] (Source: Haematologica)
Source: Haematologica - November 1, 2009 Category: Hematology Authors: Dictor M, Ek S, Sundberg M, Warenholt J, György C, Sernbo S, Gustavsson E, Abu-Alsoud W, Wadström T, Borrebaeck C Tags: Haematologica Source Type: journals

Liver X receptor alpha (LXRalpha) as a therapeutic target in chronic lymphocytic leukemia (CLL).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19875628 [PubMed - in process] (Source: Journal of Leukocyte Biology)
Source: Journal of Leukocyte Biology - October 31, 2009 Category: Hematology Authors: Christopherson KW, Landay A Tags: J Leukoc Biol Source Type: journals

U.S. Approves Ofatumumab for Refractory Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ofatumumab, a monoclonal antibody targeting the CD20 antigen on the surface of B cells, has been approved for the treatment of chronic lymphocytic leukemia in patients who are refractory to other treatments,... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - October 31, 2009 Category: Cancer & Oncology Source Type: news

Body Size, Recreational Physical Activity, and B-Cell Non-Hodgkin Lymphoma Risk Among Women in the California Teachers StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nutritional status and physical activity are known to alter immune function, which may be relevant to lymphomagenesis. The authors examined body size measurements and recreational physical activity in relation to risk of B-cell non-Hodgkin lymphoma (NHL) in the prospective California Teachers Study. Between 1995 and 2007, 574 women were diagnosed with incident B-cell NHL among 121,216 eligible women aged 22–84 years at cohort entry. Multivariable-adjusted relative risks and 95% confidence intervals were estimated by fitting Cox proportional hazards models for all B-cell NHL combined and for the 3 most common subtypes...
Source: American Journal of Epidemiology - October 30, 2009 Category: Epidemiology Authors: Lu, Y., Prescott, J., Sullivan-Halley, J., Henderson, K. D., Ma, H., Chang, E. T., Clarke, C. A., Horn-Ross, P. L., Ursin, G., Bernstein, L. Tags: RESEARCH-ARTICLE Source Type: journals

FDA Approves New Leukemia DrugEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This week the FDA granted fast-track approval of ofatumumab (Arzerra) for the treatment of chronic lymphocytic leukemia (CLL). (Source: American Cancer Society :: News and Features)
Source: American Cancer Society :: News and Features - October 30, 2009 Category: Cancer & Oncology Source Type: organizations

Treatment of cutaneous tumors with topical 5% imiquimod creamEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Our experience confirms imiquimod as an effective treatment option for several types of cutaneous tumors, especially in patients without the cutaneous comorbidities cited above and with low-risk tumors. Imiquimod has a relatively low cost compared to other therapeutic options and can be delivered via ambulatory care to patients with surgery contraindications, and its side effects are tolerable. (Source: Clinics)
Source: Clinics - October 30, 2009 Category: Journals (General) Source Type: journals

Lymphoma Research Foundation Announces Recipients Of CLL/SLL Research Initiative GrantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 30, 2009 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion In relapsed/refractory CLL, OBL combined with FC offers patients who achieve complete or partial remission, as well as those who have fludarabine-sensitive disease, a significant survival benefit. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2009 Category: Cancer & Oncology Authors: O'Brien, Moore, Boyd, Larratt, Skotnicki, Koziner, Chanan-Khan, Seymour, Gribben, Itri, Rai Tags: Combined Therapy Hematologic Malignancies Source Type: journals

Karyotype-specific microRNA signature in chronic lymphocytic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study we also found that IGHV unmutated, high expression of ZAP-70 protein, and low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion, whereas in those harboring trisomy 12 only high expression of the miR-181a, among the analyzed parameters, suggested more aggressive disease. Thus, the use of the microRNA-based classifications may yield clinically useful biomarkers of tumor behavior in CLL. (Source: Blood)
Source: Blood - October 29, 2009 Category: Hematology Authors: Visone, R., Rassenti, L. Z., Veronese, A., Taccioli, C., Costinean, S., Aguda, B. D., Volinia, S., Ferracin, M., Palatini, J., Balatti, V., Alder, H., Negrini, M., Kipps, T. J., Croce, C. M. Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: journals

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blastsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Understanding how the immune system in patients with cancer interacts with malignant cells is critical for the development of successful immunotherapeutic strategies. We studied peripheral blood from newly diagnosed patients with acute myeloid leukemia (AML) to assess the impact of this disease on the patients' T cells. The absolute number of peripheral blood T cells is increased in AML compared with healthy controls. An increase in the absolute number of CD3+56+ cells was also noted. Gene expression profiling on T cells from AML patients compared with healthy donors demonstrated global differences in transcription suggest...
Source: Blood - October 29, 2009 Category: Hematology Authors: Le Dieu, R., Taussig, D. C., Ramsay, A. G., Mitter, R., Miraki-Moud, F., Fatah, R., Lee, A. M., Lister, T. A., Gribben, J. G. Tags: Immunobiology, Myeloid Neoplasia Source Type: journals

The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study identifies a novel agent with significant clinical potential. [Cancer Res 2009;69(21):8366–75] (Source: Cancer Research)
Source: Cancer Research - October 29, 2009 Category: Cancer & Oncology Authors: McElligott, A. M., Maginn, E. N., Greene, L. M., McGuckin, S., Hayat, A., Browne, P. V., Butini, S., Campiani, G., Catherwood, M. A., Vandenberghe, E., Williams, D. C., Zisterer, D. M., Lawler, M. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: British Journal of Haematology)
Source: British Journal of Haematology - October 29, 2009 Category: Hematology Authors: Parameswaran Anoop, Andy Wotherspoon, Estella Matutes Source Type: journals

FDA Approves Ofatumumab for Refractory Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has granted accelerated approval of ofatumumab intravenous infusion for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 28, 2009 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

FDA approves leukaemia drug useEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration (FDA) has approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukaemia (CLL) who do not respond to Campath or chemotherapy drug fludarabine. (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 28, 2009 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Treatment for Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Arzerra is approved... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - October 28, 2009 Category: Cancer & Oncology Source Type: news

Health News of the DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day:Fewer than half of patients with fatigue get explanation for their symptoms within a year http://bit.ly/ZrtG1"Smoking's Damage Swift, Irreversible" - inflicting damage on the arteries with the very first puffs http://bit.ly/7zqXGMigraine is associated with a twofold increased risk of ischaemic stroke among people who have migraine with aura http://bit.ly/QltjnMany Tout Curative Properties of Titanium, Copper, Silver and Gold...
Source: Clinical Cases and Images - October 28, 2009 Category: Journals (General) Tags: Health News of the Day Source Type: info

Arzerra Approved for Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Arzerra Approved for Chronic Lymphocytic LeukemiaCategory: Health NewsCreated: 10/27/2009 12:10:00 PMLast Editorial Review: 10/28/2009 (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 28, 2009 Category: Cancer & Oncology Source Type: consumer

Arzerra Approved for Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Arzerra Approved for Chronic Lymphocytic LeukemiaCategory: Health NewsCreated: 10/27/2009 12:10:00 PMLast Editorial Review: 10/28/2009 (Source: MedicineNet Crohn's Disease General)
Source: MedicineNet Crohn's Disease General - October 28, 2009 Category: Gastroenterology Source Type: consumer